125 related articles for article (PubMed ID: 35703792)
1. Number of Worrisome Features and Risk of Malignancy in Intraductal Papillary Mucinous Neoplasm.
Zelga P; Hernandez-Barco YG; Qadan M; Ferrone CR; Kambadakone A; Horick N; Jah A; Warshaw AL; Lillemoe KD; Balakrishnan A; Fernández-Del Castillo C
J Am Coll Surg; 2022 Jun; 234(6):1021-1030. PubMed ID: 35703792
[TBL] [Abstract][Full Text] [Related]
2. Long-term surveillance of branch-duct intraductal papillary mucinous neoplasms without worrisome or high-risk features.
Lattimore CM; Kane WJ; Subbarao S; Venitti C; Cramer CL; Turkheimer LM; Bauer TW; Turrentine FE; Zaydfudim VM
J Surg Oncol; 2023 Dec; 128(7):1087-1094. PubMed ID: 37530526
[TBL] [Abstract][Full Text] [Related]
3. [Diagnostic efficacy for predicting intraductal papillary mucinous neoplasms of the pancreas with high grade dysplasia or invasive carcinoma based on the surgery indications in different guidelines].
Li B; Guo SW; Shi XH; Shen S; Zhang GX; Gao SZ; Pan YQ; Xu XF; Jin G
Zhonghua Wai Ke Za Zhi; 2021 May; 59(5):359-365. PubMed ID: 33915626
[No Abstract] [Full Text] [Related]
4. A retrospective study of intraductal papillary neoplasia of the pancreas (IPMN) under surveillance.
Johansson K; Kaprio T; Nieminen H; Lehtimäki TE; Lantto E; Haglund C; Seppänen H
Scand J Surg; 2022; 111(1):14574969221076792. PubMed ID: 35333109
[TBL] [Abstract][Full Text] [Related]
5. Indication for resection and possibility of observation for intraductal papillary mucinous neoplasm with high-risk stigmata.
Abe K; Kitago M; Masugi Y; Iwasaki E; Yagi H; Abe Y; Hasegawa Y; Fukuhara S; Hori S; Tanaka M; Nakano Y; Yokose T; Shimane G; Sakamoto M; Kitagawa Y
Pancreatology; 2021 Jun; 21(4):755-762. PubMed ID: 33632666
[TBL] [Abstract][Full Text] [Related]
6. International Consensus Guidelines parameters for the prediction of malignancy in intraductal papillary mucinous neoplasm are not properly weighted and are not cumulative.
Roch AM; Ceppa EP; DeWitt JM; Al-Haddad MA; House MG; Nakeeb A; Schmidt CM
HPB (Oxford); 2014 Oct; 16(10):929-35. PubMed ID: 25077378
[TBL] [Abstract][Full Text] [Related]
7. Cyst location and presence of high grade dysplasia or invasive cancer in intraductal papillary mucinous neoplasms of the pancreas: a seven institution study from the central pancreas consortium.
Kerlakian S; Dhar VK; Abbott DE; Kooby DA; Merchant NB; Kim HJ; Martin RC; Scoggins CR; Bentrem DJ; Weber SM; Maithel SK; Ahmad SA; Patel SH
HPB (Oxford); 2019 Apr; 21(4):482-488. PubMed ID: 30361110
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of efficacy of pancreatic juice cytology for risk classification according to international consensus guidelines in patients with intraductal papillary mucinous neoplasm; a retrospective study.
Yamakawa K; Masuda A; Nakagawa T; Shiomi H; Toyama H; Takenaka M; Sakai A; Kobayashi T; Tsujimae M; Ashina S; Yamada Y; Tanaka T; Tanaka S; Nakano R; Sato Y; Ikegawa T; Kurosawa M; Fujigaki S; Kutsumi H; Itoh T; Fukumoto T; Kodama Y
Pancreatology; 2019 Apr; 19(3):424-428. PubMed ID: 30857854
[TBL] [Abstract][Full Text] [Related]
9. International evidence-based Kyoto guidelines for the management of intraductal papillary mucinous neoplasm of the pancreas.
Ohtsuka T; Fernandez-Del Castillo C; Furukawa T; Hijioka S; Jang JY; Lennon AM; Miyasaka Y; Ohno E; Salvia R; Wolfgang CL; Wood LD
Pancreatology; 2024 Mar; 24(2):255-270. PubMed ID: 38182527
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of branch-duct intraductal papillary mucinous neoplasms with No change in first 5 Years of diagnosis.
Lee BS; Nguyen AK; Tekeste TF; Chang K; Girgis A; Adeyemo M; Hanna MS; Yao JF; Kwok KK; Giap AQ; Hunt GC; Chaya CT; Kao KT; Attam R; Ko A; Pio JR; Tovar S; Lim BS
Pancreatology; 2021 Jan; 21(1):144-154. PubMed ID: 33309223
[TBL] [Abstract][Full Text] [Related]
11. Identification of patients with branch-duct intraductal papillary mucinous neoplasm and very low risk of cancer: multicentre study.
Tamburrino D; de Pretis N; Pérez-Cuadrado-Robles E; Uribarri-Gonzalez L; Ateeb Z; Belfiori G; Maisonneuve P; Capurso G; Vanella G; Petrone MC; Arcidiacono PG; Vaalavuo Y; Frulloni L; Dominguez-Muñoz JE; Deprez PH; Falconi M; Del Chiaro M; Crippa S; Laukkarinen J
Br J Surg; 2022 Jun; 109(7):617-622. PubMed ID: 35511697
[TBL] [Abstract][Full Text] [Related]
12. "Trivial" Cysts Redefine the Risk of Cancer in Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Potential Target for Follow-Up Discontinuation?
Marchegiani G; Andrianello S; Pollini T; Caravati A; Biancotto M; Secchettin E; Bonamini D; Malleo G; Bassi C; Salvia R
Am J Gastroenterol; 2019 Oct; 114(10):1678-1684. PubMed ID: 31449158
[TBL] [Abstract][Full Text] [Related]
13. Validation of the 2012 Fukuoka Consensus Guideline for Intraductal Papillary Mucinous Neoplasm of the Pancreas From a Single Institution Experience.
Yu S; Takasu N; Watanabe T; Fukumoto T; Okazaki S; Tezuka K; Sugawara S; Hirai I; Kimura W
Pancreas; 2017 Aug; 46(7):936-942. PubMed ID: 28697135
[TBL] [Abstract][Full Text] [Related]
14. Progression vs Cyst Stability of Branch-Duct Intraductal Papillary Mucinous Neoplasms After Observation and Surgery.
Marchegiani G; Pollini T; Andrianello S; Tomasoni G; Biancotto M; Javed AA; Kinny-Köster B; Amini N; Han Y; Kim H; Kwon W; Kim M; Perri G; He J; Bassi C; Goh BK; Katz MH; Jang JY; Wolfgang C; Salvia R
JAMA Surg; 2021 Jul; 156(7):654-661. PubMed ID: 34009303
[TBL] [Abstract][Full Text] [Related]
15. Importance of each high-risk stigmata and worrisome features as a predictor of high-grade dysplasia in intraductal papillary mucinous neoplasms of the pancreas.
Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
Pancreatology; 2020 Jul; 20(5):895-901. PubMed ID: 32624417
[TBL] [Abstract][Full Text] [Related]
16. The safety and benefit of pancreatic juice cytology under ERCP in IPMN patients.
Yoshioka T; Shigekawa M; Yamai T; Suda T; Kegasawa T; Iwahashi K; Ikezawa K; Sakamori R; Yakushijin T; Hiramatsu N; Tatsumi T; Takehara T
Pancreatology; 2016; 16(6):1020-1027. PubMed ID: 27567445
[TBL] [Abstract][Full Text] [Related]
17. Histopathological evaluation of resected intraductal papillary mucinous neoplasms reveals distinct patterns of invasion in associated carcinomas.
Rift CV; Lund EL; Scheie D; Hansen CP; Hasselby JP
Hum Pathol; 2021 Jul; 113():47-58. PubMed ID: 33915115
[TBL] [Abstract][Full Text] [Related]
18. Branch duct-intraductal papillary mucinous neoplasms (BD-IPMNs): an MRI-based radiomic model to determine the malignant degeneration potential.
Flammia F; Innocenti T; Galluzzo A; Danti G; Chiti G; Grazzini G; Bettarini S; Tortoli P; Busoni S; Dragoni G; Gottin M; Galli A; Miele V
Radiol Med; 2023 Apr; 128(4):383-392. PubMed ID: 36826452
[TBL] [Abstract][Full Text] [Related]
19. Validation of the clinical utility of 4 guidelines in the initial triage of mucinous cystic lesions of the pancreas based on cross-sectional imaging: Experience with 188 surgically-treated patients.
Park RHS; Lim GRS; Wu JJY; Koh YX; Teo JY; Cheow PC; Chan CY; Ooi LLPJ; Chung AYF; Goh BKP
Eur J Surg Oncol; 2020 Nov; 46(11):2114-2121. PubMed ID: 32828582
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Malignancy Potential in Intraductal Papillary Mucinous Neoplasms of the Pancreas on MDCT.
Chai L; Zhu N; Wang Q; Wang T; Chai W
Acad Radiol; 2021 May; 28(5):679-686. PubMed ID: 32591278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
